← Home / ASPIRE BIOPHARMA HOLDINGS, INC. (ASBP)
Stock Analysis
ASPIRE BIOPHARMA HOLDINGS, INC. (ASBP)
ASBP
ASBP · Market data
6.52 -2.98%
Track ASBP in your personal workspace Monitor performance, SPY relative strength and WOI View from your watchlist.
Alert me when ASBP price is:
52W Range Position
27%
LOWMIDHIGH
Trend
Constructive
Momentum
Neutral
Updated: 2026-08-02 16:43 UTC
WOI Investment Thesis
Constructive
Confirmation improves above 17.85. Holding above 6.11 keeps the current thesis intact.
⚖️
✓
Fundamentals
Insufficient / Negative
✓
Price Structure
Constructive
•
Momentum
Neutral
×
Breakout Confirmation
Pending
Risk Level
Moderate
Analysis Scope
1Y Daily
Key Decision Levels
✓
Hold Above
Structure remains valid above support.
6.11
↗
Break Above
Confirmation improves above resistance.
17.85
🎯
Next Objective
Pattern-derived target if setup continues.
—
×
Thesis Break
Scenario weakens below invalidation.
Below 6.11
Recent Company Events
SEC VERIFIED
Latest material filings
JUN
12
◆
M&A
HIGH
ASBP merger or acquisition update
Purchase Agreement On June 10, 2026, Aspire Biopharma Holdings, Inc.
8-K Filing • SEC EDGAR
What's Driving ASBP?
📈 Technical recovery is improving
Momentum is Neutral. Watch 17.85 for confirmation and 6.11 for structure risk.
💼 Business quality remains relevant
Fundamentals remain relevant. Check growth, profitability, cash flow and balance sheet quality.
⚠️ Key risk remains
losing 5.75 would weaken the current structure.
Full Analysis Workspace
Technical Signal
Waiting for Confirmation
▲
No confirmed breakout yet. Watch the next level and momentum behavior.
RSI(14)
51.3
◎
How to read this setup
The nearest decision zone is framed by support around 5.75 and resistance near 17.85. Clearing resistance would strengthen the constructive case, while a failure through support would damage the present setup.
Price Chart
ASBP — 1D Chart
Open Full Workspace
Valuation Snapshot (TTM)
Classic valuation · Ratios use trailing twelve months
Updated 2026-07-31
Spec
Speculative premium
Valuation is very demanding relative to current fundamentals; expectations are high.
Market Cap
$1.1M
Company size
P/E
-0.1
Not meaningful
P/S
176.1
Very high
P/B
0.3
Low book multiple
Source: SEC TTM data via WOI valuation cache Not financial advice
Business Lens
Financial pressure is elevated
Financial conditions require selective monitoring.
↗
Revenue Growth
Insufficient
●
Profitability
Negative
≈
Cash Flow
Pressured
⚖
Balance Sheet
Strong
💵 Revenue
28,353
≈ Insufficient
📈 Net Income
-3.22M
↘ Negative
🧮 EPS (Basic)
-20.57
↘ Negative
ASPIRE BIOPHARMA HOLDINGS, INC.
Related Opportunities